Information Provided By: 
Fly News Breaks for April 28, 2017
BMRN
Apr 28, 2017 | 07:26 EDT
Deutsche Bank analyst Andrew Peters believes the FDA approval of BioMarin's Brineura is another important step in the company's evolution. The addition of another $300M-plus product further underscores BioMarin's long-term growth profile the analyst tells investors in a research note. Peters raised his price target for the shares to $105 from $103 and reiterates a Buy rating on BioMarin.
News For BMRN From the Last 2 Days
There are no results for your query BMRN
